WO2002058696A3 - The use of substituted azetidinone compounds for the treatment of sitosterolemia - Google Patents

The use of substituted azetidinone compounds for the treatment of sitosterolemia Download PDF

Info

Publication number
WO2002058696A3
WO2002058696A3 PCT/US2002/001195 US0201195W WO02058696A3 WO 2002058696 A3 WO2002058696 A3 WO 2002058696A3 US 0201195 W US0201195 W US 0201195W WO 02058696 A3 WO02058696 A3 WO 02058696A3
Authority
WO
WIPO (PCT)
Prior art keywords
sitosterolemia
treatment
substituted azetidinone
azetidinone compounds
sterol
Prior art date
Application number
PCT/US2002/001195
Other languages
French (fr)
Other versions
WO2002058696A2 (en
Inventor
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23006987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002058696(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MXPA03006729A priority Critical patent/MXPA03006729A/en
Priority to NZ526532A priority patent/NZ526532A/en
Priority to JP2002559030A priority patent/JP4711600B2/en
Priority to PL364280A priority patent/PL205343B1/en
Priority to EP02709050A priority patent/EP1355644B1/en
Priority to KR1020037009673A priority patent/KR100820983B1/en
Priority to MEP-2008-268A priority patent/ME00145B/en
Priority to SI200230373T priority patent/SI1355644T1/en
Priority to HU0303929A priority patent/HU230435B1/en
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU2002243557A priority patent/AU2002243557B2/en
Priority to DE60212801T priority patent/DE60212801T2/en
Priority to BR0206641-6 priority patent/BRPI0206641B8/en
Priority to SK946-2003A priority patent/SK287746B6/en
Priority to CA002434430A priority patent/CA2434430A1/en
Priority to RU2003126187A priority patent/RU2756946C2/en
Priority to IL15642202A priority patent/IL156422A0/en
Publication of WO2002058696A2 publication Critical patent/WO2002058696A2/en
Publication of WO2002058696A3 publication Critical patent/WO2002058696A3/en
Priority to IL156422A priority patent/IL156422A/en
Priority to ZA2003/05691A priority patent/ZA200305691B/en
Priority to NO20033359A priority patent/NO333695B1/en
Priority to HK03107963A priority patent/HK1055679A1/en
Priority to CY20061101212T priority patent/CY1106149T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.
PCT/US2002/001195 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia WO2002058696A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
AU2002243557A AU2002243557B2 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
DE60212801T DE60212801T2 (en) 2001-01-26 2002-01-25 USE OF AZETIDINONE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF SITOSTEROL HEMIA
JP2002559030A JP4711600B2 (en) 2001-01-26 2002-01-25 Use of substituted azetidinone compounds for the treatment of sitosterolemia
PL364280A PL205343B1 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
EP02709050A EP1355644B1 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
KR1020037009673A KR100820983B1 (en) 2001-01-26 2002-01-25 A pharmaceutical composition comprising substituted azetidinone compounds
MEP-2008-268A ME00145B (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
SI200230373T SI1355644T1 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
HU0303929A HU230435B1 (en) 2001-01-26 2002-01-25 Use of substituted azetidinone compounds for treatment of sitosterolemia
NZ526532A NZ526532A (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
IL15642202A IL156422A0 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
MXPA03006729A MXPA03006729A (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia.
CA002434430A CA2434430A1 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
SK946-2003A SK287746B6 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia
BR0206641-6 BRPI0206641B8 (en) 2001-01-26 2002-01-25 use of a sterol absorption inhibitor
RU2003126187A RU2756946C2 (en) 2001-01-26 2002-01-25 Application of substituted azetidinones for treatment of sytosterolemia
IL156422A IL156422A (en) 2001-01-26 2003-06-12 Use of substituted azetidinone compounds for manufacturing of sitosterolemia medicament
ZA2003/05691A ZA200305691B (en) 2001-01-26 2003-07-23 The use of substituted azetidione compounds for the treatment of sitosterolemia
NO20033359A NO333695B1 (en) 2001-01-26 2003-07-25 Use of a sterol absorption inhibitor for the treatment of sitosterolemia
HK03107963A HK1055679A1 (en) 2001-01-26 2003-11-04 The use of substituted azetidinone compounds for the treatment of sitosterolemia
CY20061101212T CY1106149T1 (en) 2001-01-26 2006-08-29 THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEPOLEMIA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26464501P 2001-01-26 2001-01-26
US60/264,645 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002058696A2 WO2002058696A2 (en) 2002-08-01
WO2002058696A3 true WO2002058696A3 (en) 2003-03-13

Family

ID=23006987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001195 WO2002058696A2 (en) 2001-01-26 2002-01-25 The use of substituted azetidinone compounds for the treatment of sitosterolemia

Country Status (33)

Country Link
US (2) US7417039B2 (en)
EP (1) EP1355644B1 (en)
JP (2) JP4711600B2 (en)
KR (2) KR100820983B1 (en)
CN (1) CN100522159C (en)
AR (1) AR035533A1 (en)
AT (1) ATE331512T1 (en)
AU (1) AU2002243557B2 (en)
BR (1) BRPI0206641B8 (en)
CA (1) CA2434430A1 (en)
CY (1) CY1106149T1 (en)
CZ (1) CZ305202B6 (en)
DE (1) DE60212801T2 (en)
DK (1) DK1355644T3 (en)
ES (1) ES2266459T3 (en)
HK (1) HK1055679A1 (en)
HU (1) HU230435B1 (en)
IL (2) IL156422A0 (en)
ME (1) ME00145B (en)
MX (1) MXPA03006729A (en)
MY (1) MY138301A (en)
NO (1) NO333695B1 (en)
NZ (1) NZ526532A (en)
PE (1) PE20020850A1 (en)
PL (1) PL205343B1 (en)
PT (1) PT1355644E (en)
RS (1) RS50406B (en)
RU (2) RU2756946C2 (en)
SI (1) SI1355644T1 (en)
SK (1) SK287746B6 (en)
TW (1) TWI337076B (en)
WO (1) WO2002058696A2 (en)
ZA (1) ZA200305691B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756946C2 (en) * 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Application of substituted azetidinones for treatment of sytosterolemia
US20030053981A1 (en) * 2001-01-26 2003-03-20 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
BR0212907A (en) * 2001-09-21 2004-10-13 Schering Corp Methods for treating or preventing vascular inflammation using sterol absorption inhibitor (s)
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
JP2005504091A (en) * 2001-09-21 2005-02-10 シェーリング　コーポレイション Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (en) 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
DE10259245A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2318274T3 (en) * 2003-03-07 2009-05-01 Schering Corporation AZETIDINONA SUBSTITUTED COMPOUNDS, FORMULATIONS AND USE OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
KR20060056944A (en) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
KR101573316B1 (en) * 2004-03-29 2015-12-01 와이어쓰 엘엘씨 Multi-vitamin and mineral nutritional supplements
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
AR060623A1 (en) 2006-04-27 2008-07-02 Astrazeneca Ab COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
KR100966630B1 (en) * 2008-04-23 2010-06-29 에스케이텔레시스 주식회사 Quality of service offering system and method for using the same
US9817001B2 (en) * 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
TR200806300A2 (en) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Solubility enhancing pharmaceutical formulation
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
WO2011002422A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
WO2011019326A2 (en) 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
CN108558740B (en) 2010-01-27 2021-10-19 艾尼纳制药公司 S1P1 receptor modulators and salts thereof
EA201390421A1 (en) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. GPR119 RECEPTOR MODULATORS AND TREATMENT OF RELATED DISORDERS
CA2851838A1 (en) 2011-10-13 2013-04-18 Boston Heart Diagnostics Corporation Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
WO2016081471A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
MX2021011472A (en) 2015-01-06 2022-08-17 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor.
ES2929526T3 (en) 2015-06-22 2022-11-29 Arena Pharm Inc (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524595A1 (en) * 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
WO1996019450A1 (en) * 1994-12-21 1996-06-27 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997016455A1 (en) * 1995-10-31 1997-05-09 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
US5688990A (en) * 1994-03-25 1997-11-18 Shankar; Bandarpalle B. Substituted azetidinone compounds useful as hypocholesterolemic agents
US5698548A (en) * 1993-01-21 1997-12-16 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5846966A (en) * 1993-09-21 1998-12-08 Schering Corporation Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108097A (en) * 1963-10-22 Ehnojs
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
NL238796A (en) * 1958-05-07
NL127065C (en) * 1964-04-22
NL137318C (en) * 1964-06-09
FI52570C (en) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds.
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (en) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (en) * 1977-09-19 1979-04-13 Lafon Labor NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS
IT1157365B (en) * 1977-10-24 1987-02-11 Sandoz Ag MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (en) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
US4614614A (en) * 1983-03-28 1986-09-30 Ciba-Geigy Corporation Process for the manufacture of optically active azetidinones
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (en) * 1984-03-30 1987-12-11 Lafon Labor GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (en) * 1986-04-30 1989-01-20 Rech Ind NEW PROCESS FOR THE PREPARATION OF FIBRATES.
DE3621861A1 (en) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES
FR2602423B1 (en) * 1986-08-08 1989-05-05 Ethypharm Sa PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
ZA879415B (en) 1986-12-15 1989-08-30 Lilly Co Eli Antibiotic a10255 complex and factors,microorganisms,process and production therefor
JPS63156788A (en) * 1986-12-22 1988-06-29 Sanraku Inc Optically active azetidinones
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
DE3877406T2 (en) * 1987-04-28 1993-06-09 Fujisawa Astra Ltd BENZOTHIAZOLINONE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION.
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
DE3807895A1 (en) * 1988-03-10 1989-09-21 Knoll Ag PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (en) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
AU628549B2 (en) * 1989-05-12 1992-09-17 De Beers Industrial Diamond Division (Proprietary) Limited Wire drawing die
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (en) * 1989-06-30 1991-05-08 Shionogi & Co Ltd Phospholipase a2 inhibitor
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
DE69103003T2 (en) * 1990-04-13 1994-11-03 Pfizer METHOD FOR SULTAMICILLINE INTERMEDIATE PRODUCT.
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2640986B2 (en) * 1990-11-08 1997-08-13 高砂香料工業株式会社 Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
JP3144624B2 (en) * 1995-06-02 2001-03-12 杏林製薬株式会社 N-benzyldioxothiazolidylbenzamide derivative and method for producing the same
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
AU8257898A (en) * 1997-06-17 1999-01-04 Rutgers, The State University Of New Jersey Hypocholesterolemic compositions from bamboo shoots
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO1999053925A1 (en) * 1998-04-17 1999-10-28 Medical Isotopes Inc. Phytosterol formulations to lower cholesterol absorption
RU2756946C2 (en) * 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Application of substituted azetidinones for treatment of sytosterolemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524595A1 (en) * 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5698548A (en) * 1993-01-21 1997-12-16 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5846966A (en) * 1993-09-21 1998-12-08 Schering Corporation Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
US5688990A (en) * 1994-03-25 1997-11-18 Shankar; Bandarpalle B. Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996019450A1 (en) * 1994-12-21 1996-06-27 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1997016455A1 (en) * 1995-10-31 1997-05-09 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] December 1990 (1990-12-01), BELAMARICH P F ET AL: "Response to diet and cholestyramine in a patient with sitosterolemia.", XP002222942, Database accession no. NLM2251034 *
DATABASE MEDLINE [online] September 1985 (1985-09-01), SALEN G ET AL: "Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis.", XP002222944, Database accession no. NLM4067433 *
JOURNAL OF LIPID RESEARCH. UNITED STATES SEP 1985, vol. 26, no. 9, September 1985 (1985-09-01), pages 1126 - 1133, ISSN: 0022-2275 *
PEDIATRICS. UNITED STATES DEC 1990, vol. 86, no. 6, December 1990 (1990-12-01), pages 977 - 981, ISSN: 0031-4005 *

Also Published As

Publication number Publication date
DE60212801D1 (en) 2006-08-10
PL364280A1 (en) 2004-12-13
RU2003126187A (en) 2005-02-20
HUP0303929A2 (en) 2004-03-01
US20020169134A1 (en) 2002-11-14
AU2002243557B2 (en) 2006-01-05
KR20040025886A (en) 2004-03-26
IL156422A (en) 2009-06-15
ATE331512T1 (en) 2006-07-15
MY138301A (en) 2009-05-29
JP4711600B2 (en) 2011-06-29
BRPI0206641B1 (en) 2017-06-20
NO20033359D0 (en) 2003-07-25
SK287746B6 (en) 2011-08-04
HUP0303929A3 (en) 2012-12-28
CZ20032038A3 (en) 2003-12-17
CZ305202B6 (en) 2015-06-10
US20050080071A1 (en) 2005-04-14
JP2004532186A (en) 2004-10-21
JP4614460B2 (en) 2011-01-19
BRPI0206641B8 (en) 2021-05-25
NO333695B1 (en) 2013-08-26
ZA200305691B (en) 2005-02-23
ME00145B (en) 2010-10-10
KR100820983B1 (en) 2008-04-10
RU2756946C2 (en) 2021-10-07
DE60212801T2 (en) 2007-02-01
HU230435B1 (en) 2016-06-28
WO2002058696A2 (en) 2002-08-01
MXPA03006729A (en) 2003-10-24
CN100522159C (en) 2009-08-05
YU59103A (en) 2006-05-25
NZ526532A (en) 2005-01-28
RS50406B (en) 2009-12-31
JP2007091763A (en) 2007-04-12
KR20070120617A (en) 2007-12-24
PL205343B1 (en) 2010-04-30
RU2007131955A (en) 2009-02-27
CN1527707A (en) 2004-09-08
CY1106149T1 (en) 2011-06-08
TWI337076B (en) 2011-02-11
AR035533A1 (en) 2004-06-02
IL156422A0 (en) 2004-01-04
ES2266459T3 (en) 2007-03-01
HK1055679A1 (en) 2004-01-21
DK1355644T3 (en) 2006-10-23
EP1355644A2 (en) 2003-10-29
NO20033359L (en) 2003-09-25
US7417039B2 (en) 2008-08-26
EP1355644B1 (en) 2006-06-28
PT1355644E (en) 2006-11-30
CA2434430A1 (en) 2002-08-01
SI1355644T1 (en) 2006-10-31
MEP26808A (en) 2010-06-10
SK9462003A3 (en) 2004-06-08
PE20020850A1 (en) 2002-09-21
BR0206641A (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2002058696A3 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
EP1810693A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
WO2002058731A3 (en) Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2003072024A3 (en) Methods of treating vascular disease
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2007105210A3 (en) Therapeutic uses of cannabidiol compounds
DE60121440D1 (en) CANCER TREATMENT COMPOSITION CONTAINING AN ANTINEOPLASTIC AGENT AND PDE4 INHIBITOR
WO2002058733A3 (en) Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
HUP0401501A3 (en) Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
WO2006086693A3 (en) Medical devices
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2002058685A3 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
WO2004010948A3 (en) Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
GB0020504D0 (en) Therapeutic method
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002037122A3 (en) Sterol glucoside toxins
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-591/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UA UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UA UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 156422

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526532

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500564

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2002243557

Country of ref document: AU

Ref document number: 2434430

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037009673

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/05691

Country of ref document: ZA

Ref document number: 200305691

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002559030

Country of ref document: JP

Ref document number: 9462003

Country of ref document: SK

Ref document number: 1144/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 02804102X

Country of ref document: CN

Ref document number: PA/a/2003/006729

Country of ref document: MX

Ref document number: PV2003-2038

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 03064028

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2002709050

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002709050

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2038

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020037009673

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 526532

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526532

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002243557

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2002709050

Country of ref document: EP